These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1271 related items for PubMed ID: 16645966

  • 1. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 4. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Arbogast PG, Griffin MR.
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [Abstract] [Full Text] [Related]

  • 5. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 6. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 7. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC.
    Arthritis Rheum; 2006 Aug 15; 55(4):537-42. PubMed ID: 16874797
    [Abstract] [Full Text] [Related]

  • 8. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 9. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.
    Winkelmayer WC, Waikar SS, Mogun H, Solomon DH.
    Am J Med; 2008 Dec 04; 121(12):1092-8. PubMed ID: 19028206
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 04; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 11. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 04; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 04; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [Abstract] [Full Text] [Related]

  • 13. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
    Shireman TI, Rigler SK.
    Am J Geriatr Pharmacother; 2006 Sep 04; 4(3):210-8. PubMed ID: 17062321
    [Abstract] [Full Text] [Related]

  • 14. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 04; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May 04; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr 04; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 17. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May 04; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

  • 18. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 19. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F, Suissa S, Garbe E.
    Circulation; 2006 Apr 25; 113(16):1950-7. PubMed ID: 16618816
    [Abstract] [Full Text] [Related]

  • 20. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 25; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.